Fate Therapeutics Inc
NASDAQ:FATE

Watchlist Manager
Fate Therapeutics Inc Logo
Fate Therapeutics Inc
NASDAQ:FATE
Watchlist
Price: 1.01 USD 2.39% Market Closed
Market Cap: 116.5m USD

Fate Therapeutics Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Fate Therapeutics Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Fate Therapeutics Inc
NASDAQ:FATE
Operating Income
-$174.7m
CAGR 3-Years
18%
CAGR 5-Years
-7%
CAGR 10-Years
-21%
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

Fate Therapeutics Inc
Glance View

Market Cap
116.5m USD
Industry
Biotechnology

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. The company is headquartered in San Diego, California and currently employs 449 full-time employees. The company went IPO on 2013-10-01. The firm is focused on the development of programmed cellular immunotherapies for patients with cancer. The company uses human induced pluripotent stem cells (iPSCs) generated from its proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties. The firm is advancing a pipeline of programmed cellular immunotherapies, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master iPSC lines for the treatment of cancer. The firm's product pipeline includes FT596, FT538, FT576, FT536, FT573, FT819, FT500 and FT516. FT516 is an investigational off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a novel CD16 (hnCD16) Fc receptor. FT596 is an investigational off-the-shelf CAR NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.

FATE Intrinsic Value
0.24 USD
Overvaluation 76%
Intrinsic Value
Price

See Also

What is Fate Therapeutics Inc's Operating Income?
Operating Income
-174.7m USD

Based on the financial report for Sep 30, 2025, Fate Therapeutics Inc's Operating Income amounts to -174.7m USD.

What is Fate Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-21%

Over the last year, the Operating Income growth was 11%. The average annual Operating Income growth rates for Fate Therapeutics Inc have been 18% over the past three years , -7% over the past five years , and -21% over the past ten years .

Back to Top